ATTR variant amyloidosis amyloidosis, transthyretin
Conditions
Interventions
At the time of diarrhea, cholestimide 500 mg given orally, three tablets twice daily before breakfast and dinner.The maximum daily dosage is 6 tablets, and the interval between doses should be at leas
Sponsors
Yoshiki Sekijima
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 20 years or older with a diagnosis of ATTRv amyloidosis 2) Patients with diarrhea symptoms that are difficult to control with existing symptomatic medications for diarrhea (Bristol Stool Shape Scale 6 or higher) 3) Patients who are able to comply with their medication and keep an appropriate diary. 4) Patients who have given written consent based on the free will of the subject after receiving sufficient explanation for participation in this study.
Exclusion criteria
Exclusion criteria: Patients who do not meet any of the following exclusion criteria will be included. (1) Patients for whom consent cannot be obtained (2) Patients who have contraindications to the use of the study drug (patients with complete obstruction of the biliary tract, patients with intestinal obstruction, patients with a history of hypersensitivity to the components of Corevine Tablets 500 mg). (3) Other patients who are judged by the principal investigator to be unsuitable as subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the frequency of diarrhea before and after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the following items before and after treatment. 1 Bristol Stool Form Scale 2 primary symptoms 3 Blood concentration of 7a-hydroxy-4-cholesten-3-one(C4) 4 mBMI 5 EQ-5D-5L | — |
Contacts
Public ContactMochizuki Yusuke
Shinshu university department of medicine
Outcome results
None listed